These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17661202)

  • 1. A Comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients.
    Faries MB; Gupta RK; Ye X; Lee C; Yee R; Leopoldo Z; Essner R; Foshag LJ; Elashoff D; Morton DL
    Cancer Invest; 2007 Aug; 25(5):285-93. PubMed ID: 17661202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
    Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
    Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
    Hsueh EC; Gupta RK; Qi K; Yee R; Leopoldo ZC; Morton DL
    Cancer J Sci Am; 1997; 3(6):364-70. PubMed ID: 9403050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
    Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
    Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma.
    Garnier JP; Letellier S; Cassinat B; Lebbé C; Kerob D; Baccard M; Morel P; Basset-Seguin N; Dubertret L; Bousquet B; Stoitchkov K; Le Bricon T
    Eur J Cancer; 2007 Mar; 43(4):816-21. PubMed ID: 17276671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
    Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
    Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
    Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
    Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum markers in skin melanoma--preliminary study.
    Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
    Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
    Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
    Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy.
    Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD
    Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
    Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
    J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.
    Krähn G; Kaskel P; Sander S; Waizenhöfer PJ; Wortmann S; Leiter U; Peter RU
    Anticancer Res; 2001; 21(2B):1311-6. PubMed ID: 11396205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.
    Harpio R; Einarsson R
    Clin Biochem; 2004 Jul; 37(7):512-8. PubMed ID: 15234232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
    Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
    J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
    Klimek VM; Williams L; Chapman PB
    Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
    Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
    Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S-100beta and MIA in advanced melanoma in relation to prognostic factors.
    Auge JM; Molina R; Filella X; Bosch E; Gonzalez Cao M; Puig S; Malvehy J; Castel T; Ballesta AM
    Anticancer Res; 2005; 25(3A):1779-82. PubMed ID: 16033099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
    Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
    Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.